Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-06-17
2008-06-17
Shameem, Golam M. M. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S452000, C548S512000, C548S513000, C514S412000
Reexamination Certificate
active
07388027
ABSTRACT:
The present invention relates to bicyclic compounds according to formula I, pharmaceutical compositions containing such compounds and methods of using such compounds in the treatment of androgen receptor-associated conditions, such as age-related diseases, for example sarcopenia,wherein R1, R2, R2′R5, G, n and W are defined herein.
REFERENCES:
patent: 5556909 (1996-09-01), Desai
patent: 5688808 (1997-11-01), Jones et al.
patent: 5688810 (1997-11-01), Jones et al.
patent: 5693646 (1997-12-01), Jones et al.
patent: 5693647 (1997-12-01), Jones et al.
patent: 5696127 (1997-12-01), Jones et al.
patent: 5696130 (1997-12-01), Jones et al.
patent: 5696133 (1997-12-01), Jones et al.
patent: 5811374 (1998-09-01), Bertram et al.
patent: WO 96/19458 (1996-06-01), None
patent: WO 97/49709 (1997-12-01), None
U.S. Appl. No. 10/984,502, filed Nov. 9, 2004, Bi et al.
U.S. Appl. No. 11/048,437, filed Feb. 1, 2005, Nirschl et al.
U.S. Appl. No. 11/048,439, filed Feb. 1, 2005, Hamann et al.
U.S. Appl. No. 11/070,025, filed Mar. 2, 2005, Li et al.
U.S. Appl. No. 11/070,808, filed Mar. 2, 2005, Nirschl et al.
Banz, W.J. et al., “Effects of Soy Protein and Soy Phytoestrogens on Symptoms Associated with Cardiovascular Disease in Rats”, Journal of Medicinal Food, vol. 2, Nos. 3-4, pp. 271-273 (1999).
Boeijen, A. et al., “Combinatorial Chemistry of Hydantoins”, Bioorganic & Medicinal Chemistry Letters, vol. 8, pp. 2375-2380 (1998).
Bourguet, W. et al., “Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-α”, Nature, vol. 375, pp. 377-382 (1995).
Brzozowski, A.M. et al., “Molecular basis of agonism and antagonism in the oestrogen receptor”, Nature, vol. 389, pp. 753-758 (1997).
Evans, R.M., “The Steroid and Thyroid Hormone Receptor Superfamily”, Science, vol. 240, pp. 889-895 (1988).
Grese, T.A. et al., “Molecular determinants of tissue selectivity in estrogen receptor modulators”, Proc. Natl. Acad. Sci. USA, vol. 94, pp. 14105-14110 (1997).
Hamann, L.G. et al., “Discovery of a Potent, Orally Active, Nonsteroidal Androgen Receptor Agonist: 4-Ethyl-1,2,3,4-tetrahydro-6-(trifluoromethyl)-8-pyridono[5,6-g]-quinoline (LG121071)”, J. Med. Chem., vol. 42, No. 2, pp. 210-212 (1999).
Hamann, L.G. et al., “Synthesis and Biological Activity of a Novel Series of Nonsteroidal, Peripherally Selective Androgen Receptor Antagonists Derived from 1,2-Dihydropyridono[5,6-g]quinolines”, J. Med. Chem., vol. 41, No. 4, pp. 623-639 (1998).
Hempstock, J. et al., “Growth inhibition of prostate cell lines in vitro by phyto-oestrogens”, British Journal of Urology, vol. 82, pp. 560-563 (1998).
Neri, R. et al., “A Biological Profile of a Nonsteroidal Antiandrogen, SCH 13521 (4′-Nitro-3′-Trifluoromethylisobutyranilide)”, Endocrinology, vol. 91, No. 2, pp. 427-437 (1972).
Quella, S.K. et al., “Evaluation of Soy Phytoestrogens for the Treatment of Hot Flashes in Breast Cancer Survivors: A North Central Cancer Treatment Group Trial”, Journal of Clinical Oncology, vol. 18, No. 5, pp. 1068-1074 (2000).
Regal, J.F. et al., “Dietary Phytoestrogens Have Anti-Inflammatory Activity in a Guinea Pig Model of Asthma”, Proc. Soc. Exp. Biol. Med., vol. 223, pp. 372-378 (2000).
Shiau, A.K. et al., “The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen”, Cell, vol. 95, pp. 927-937 (1998).
Smigel, K., “Breast Cancer Prevention Trial Shows Major Benefit, Some Risk”, Journal of the National Cancer Institute, vol. 90, No. 9, pp. 647-648 (1998).
Tanenbaum, D.M. et al., “Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains”, Proc. Natl. Acad. Sci. USA, vol. 95, pp. 5998-6003 (1998).
Vegeto, E. et al., “The Mechanism of RU486 Antagonism Is Dependent on the Conformation of the Carboxy-Terminal Tail of the Human Progesterone Receptor”, Cell, vol. 69, pp. 703-713 (1992).
Montes de Oca, A. et al., “Synthesis of aryl pyrrolizidines from endocyclic enecarbamates. Novel applications of the Heck arylation of 3-pyrrolines using diazonium salts”, Arkivoc, pp. 390-403 (2003).
Augeri David
Bi Yingzhi
Hamann Lawrence
Li James J.
Bristol--Myers Squibb Company
Shameem Golam M. M.
LandOfFree
Bicyclic compounds as modulators of androgen receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bicyclic compounds as modulators of androgen receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bicyclic compounds as modulators of androgen receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2798145